# **The TodS–TodT two-component regulatory system recognizes a wide range of effectors and works with DNA-bending proteins**

**Jesu´ s Lacal, Andreas Busch, Marı´a-Eugenia Guazzaroni, Tino Krell, and Juan L. Ramos†**

Department of Environmental Protection, Estación Experimental del Zaidín, Consejo Superior de Investigaciones Científicas, E-18008 Granada, Spain

Communicated by David T. Gibson, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, April 10, 2006 (received for review March 7, 2006)

**The TodS and TodT proteins form a previously unrecognized and highly specific two-component regulatory system in which the TodS sensor protein contains two input domains, each of which are coupled to a histidine kinase domain. This system regulates the expression of the genes involved in the degradation of toluene, benzene, and ethylbenzene through the toluene dioxygenase pathway. In contrast to the narrow substrate range of this catabolic pathway, the TodS effector profile is broad. TodS has basal autophosphorylation activity** *in vitro***, which is enhanced by the presence of effectors. Toluene binds to TodS with high affinity**  $(K_d = 684 \pm 13$  nM) and 1:1 stoichiometry. The analysis of the trun**cated variants of TodS reveals that toluene binds to the N-terminal** input domain ( $K_d = 2.3 \pm 0.1 \mu M$ ) but not to the C-terminal half. **TodS transphosphorylates TodT, which binds to two highly similar DNA binding sites at base pairs 107 and 85 of the promoter. Integration host factor (IHF) plays a crucial role in the activation process and binds between the upstream TodT boxes and the 10 hexamer region. In an IHF-deficient background, expression from the** *tod* **promoter drops 8-fold.** *In vitro* **transcription assays confirmed the role determined** *in vivo* **for TodS, TodT, and IHF. A functional model is presented in which IHF favors the contact between the TodT activator, bound further upstream, and the -subunit of RNA polymerase bound to the downstream promoter element. Once these contacts are established, the** *tod* **operon is efficiently transcribed.**

*Pseudomonas* | sensor kinase | toluene dioxygenase | transcriptional regulator

**M** any *Pseudomonas putida* strains are able to use benzene, toluene, and ethylbenzene as the sole carbon and energy source through the toluene dioxygenase (TOD) pathway (1). In this pathway, the aromatic hydrocarbons are oxidized to their corresponding substituted catechols, which are further metabolized to Krebs cycle intermediates (1, 2). The catabolic genes of the TOD pathway form the operon *todXFC1C2BADEGIH*, which is transcribed from a single promoter called  $P_{today}$ , located upstream from the *todX* gene (1–3). The *todST* genes are found downstream and form an independent operon that is expressed constitutively (2, 3).

TodS and TodT have been proposed to form a two-component regulatory system (TCS) that regulates the *tod* catabolic operon in *P. putida* F1 (3). TodT shows all of the characteristics of a response regulator, whereas sequence-based domain predictions indicate that the 108-kDa TodS belongs to a family of sensor histidine kinases that have not been studied at the biochemical level. TodS is predicted to comprise two supradomains, each containing a PAS/PAC sensory domain and a histidine kinase domain. The supradomains are separated by the receiver domain of a response regulator. In contrast to other histidine kinases, TodS apparently lacks transmembrane regions (3). The mode of action of this previously unrecognized type of histidine kinase has yet to be established. On the basis of moderate sequence similarity with the heme-binding oxygen sensor FixL, the C-terminal supradomain of TodS was proposed to be involved in oxygen sensing (3). Choi *et al.* (4) isolated TodS mutants that recognized aromatic compounds that are not effectors of the wild-type protein. Mutations were scattered along the C-terminal half of TodS.

The TodT protein was shown to bind to the Tod box centered at base pair  $-107$  in the  $P_{today}$  promoter (3). This site is located far from the downstream RNA polymerase-binding site. The  $P_{today}$ promoter exhibits a well defined  $-10$  base pair region, although there is no base pair  $-35$  consensus region, consistent with the fact that  $P_{today}$  belongs to the "extended promoter" type that resembles *P. putida*  $\sigma^{70}$ -dependent promoters (5). Because TodT binds far from the RNA polymerase-binding site, we hypothesize that DNA bending is required for transcription activation, which implies that the activation mechanism involves a direct contact between TodT and the RNA polymerase. This type of enhancer-activation system is well documented for regulators of the NtrC family working in conjunction with RNA polymerase/ $\sigma^{54}$  (6, 7).

This study was undertaken to characterize this previously unrecognized TCS. We first addressed questions related to signal sensing and transmission, such as the definition of the effector profile of TodS, the thermodynamic characteristics of the interaction of TodS with aromatic hydrocarbons, the modulatory effect of effector binding on the autophosphorylation activity of TodS, and the detection of TodS–TodT transphosphorylation activity. We then explored the interaction of TodT with  $P_{today}$  and the involvement of DNA-bending proteins such as IHF in the mechanism of transcriptional activation. A functional model for transcription activation mediated by this TCS is discussed.

#### **Results**

*P. putida* DOT-T1E grows on toluene, ethylbenzene, and benzene. We had previously generated *todT* and *todS* mutants of this strain, which failed to grow on the above hydrocarbons as the sole carbon source (2). The chromosomal *todT* mutation was complemented by the *todT* gene supplied in trans in pJLC1. However, the *todS* mutant was complemented by pMIR66 (bearing *todST*) only. These results indicated that both TodS and TodT are needed for induction of the TOD pathway.

*P. putida* KT2440 does not have the *tod* genes on its chromosome and cannot grow on toluene. We transferred pMIR77 ( $P_{today}$ ::'lacZ) to this strain, and, regardless of the presence of toluene, no --galactosidase expression took place. When KT2440 (pMIR77) was transformed with pMIR66, induction took place in response to toluene, and  $\beta$ -galactosidase levels reached 4,500 Miller units. However, when the plasmid bore a mutation in *todS* (pJLC1) or  $\text{tolT}$  (pJLC2), no induction from  $P_{\text{today}}$  occurred (Table 1). There-

Conflict of interest statement: No conflicts declared.

Abbreviations: CTD, C-terminal domain; CTodS, C-terminal TodS fragment; IHF, integration host factor; NTodS, N-terminal TodS fragment; TCS, two-component regulatory system; TOD, toluene dioxygenase.

<sup>&</sup>lt;sup>†</sup>To whom correspondence should be addressed at: Estación Experimental del Zaidín, Consejo Superior de Investigaciones Científicas, Calle Professor Albareda 1, E-18008 Granada, Spain. E-mail: jlramos@eez.csic.es

<sup>© 2006</sup> by The National Academy of Sciences of the USA

#### **Table 1. Bacterial strains and plasmids used in this study**



ApR, CmR, GmR, KmR, RifR, TcR indicate resistance to ampicillin, chloramphenicol, gentamicin, kanamycin, rifampicin, and tetracycline, respectively. Tol $^+$  and Tol<sup>-</sup> indicate either that the strain grows or fails to grow on toluene, respectively.

fore, although *P. putida* codifies for a large number of TCSs encoded in its chromosome (8, 9), our results indicate that the TodS–TodT interaction is highly specific and that the Tod regulatory proteins cannot be replaced by proteins of any other TCS.



**Fig. 1.** Induction of *PtodX* by TodS–TodT in response to a wide range of aromatics. P. putida DOT-T1E bearing pMIR77 (P<sub>todX</sub>:'lacZ) was grown on M9 medium with 1 mM of the indicated effector. When turbidity of the cultures was 0.8,  $\beta$ -galactosidase activity was determined. Tested compounds that did not induce were as follows: *o*-xylene, *m*- and *p*-ethyltoluene; *o*-, *m*-, and *p*-nitrotoluene; *o*-chloro-, *o*-, *m*-, and *p-*iodotoluene; propyl-, butyl-, and isobutylbenzene; 1,2,3-, 1,3,5-, 1,2,4-trimethylbenzene; and benzamide. T, toluene; B, benzene.



**Fig. 2.** Isothermal titration calorimetry data for the binding of toluene to TodS and its recombinant fragments NTodS and CTodS. (*Upper*) Heat changes are shown. (*Lower*) Integrated peak areas are shown. (*A*) Titration of buffer with 1 mM toluene. ( $B$ ) Titration of 15  $\mu$ M TodS with 1 mM toluene. (C) Titration of 12  $\mu$ M NTodS with 0.8 mM toluene. (*D*) Titration of 8  $\mu$ M CTodS with 1 mM toluene. Integrated peak areas are shown for heat changes in *B* (*E*) and *C* (*F*).

**Effector Profile of the TodS–TodT System.** The range of effectors recognized by catabolic pathway regulators is typically larger than the range of substrates metabolized by the pathway (10–13). To identify the range of aromatic compounds that activate transcription from  $P_{today}$  we measured induction by using the  $P_{today}$ :*lacZ* fusion. Basal activity was  $1.9 \pm 0.7$  Miller units, but the addition of benzene to the culture led to an almost 50-fold increase in activity (Fig. 1). Then we analyzed benzene derivatives with different substituents. The data indicated that a short lateral chain, such as in toluene, increased the activation of *PtodX* significantly, whereas longer alkyl chains resulted in a significant decrease in the inducing capability of *PtodX*. This finding is exemplified by ethylbenzene, which was a poor effector, whereas *n*-propylbenzene showed no inducer activity (Fig. 1). Chloro-, fluoro-, and nitrobenzene significantly induced expression from  $P_{today}$  (Fig. 1).

Because toluene was the best tested effector, we evaluated different substituents in the aromatic ring at C2, C3, and C4. A number of substituents were permissible at positions 3 and 4 in the aromatic ring of toluene, allowing for methyl, amino, fluoro, bromo, and chloro substitutions (Fig. 1). In contrast, in position 2, only fluoro and amino substituents were permitted. This result evidenced that the regulator profile was significantly broader than the substrate range accepted by the pathway.

**Isothermal Titration Calorimetry.** Purified His-tag TodS protein was used to determine the thermodynamic parameters for the binding of toluene and ethylbenzene. Fig. 2 shows that the heat changes



**Fig. 3.** The catalytic properties of TodS. (*A Upper*) Autophosphorylation in the presence and absence of toluene. Experiments were carried out in parallel, and the graph (*A Lower*) shows the densitometric analysis of the gels. (*B*) Dephosphorylation kinetics. (*C*) Transphosphorylation to TodT. Conditions for these assays are described in *Materials and Methods*.

obtained for the injection of toluene into buffer were negligible. Binding of toluene to TodS (Fig. 2*B*) was driven by favorable enthalpy ( $\Delta H = -5.5 \pm 0.1$  kcal/mol) and entropy ( $T\Delta S = 2.9 \pm 0.1$ 0.1 kcal/mol) changes. Binding was tight, with a dissociation constant of  $684 \pm 13$  nM, and the TodS: toluene binding stoichiometry was 1:1. Ethylbenzene binds to TodS in a similar fashion  $(\Delta H = -3.6 \pm 0.1 \text{ kcal/mol}; 1 \text{ kcal} = 4.18 \text{ kJ})$  but with lower affinity  $(K_d = 3.1 \pm 0.2 \mu M).$ 

Because TodS contains two PAS/PAC-type input domains, to identify the toluene-binding domain, two truncated variants of TodS were created. The N-terminal TodS fragment (NTodS), comprising residues 1–584, contained the N-terminal PAS/PAChistidine kinase domains and the receiver domain of a response regulator, whereas the C-terminal TodS fragment (CTodS), comprising residues 452–978, contained the receiver domain of a response regulator followed by the PAS/PAC-histidine kinase domains located at the C terminus of TodS. We purified both TodS variants and found that toluene bound to NTodS with a very favorable enthalpy change  $(\Delta H = -18.3 \pm 0.2 \text{ kcal/mol})$ , an affinity of 2.3  $\pm$  0.1  $\mu$ M, and a 1:1 stoichiometry (Fig. 2*C*), whereas purified CTodS did not interact with the effector (Fig. 2*D*).

**Modulation of Basal Autophosphorylation Activity of TodS by Toluene and Rate of Dephosphorylation.**A typical property of histidine kinases is the capacity to autophosphorylate in the presence of ATP. TodS was incubated with 50  $\mu$ M [ $\gamma$ -<sup>32</sup>P]ATP, and samples were taken at different times and analyzed (Fig. 3*A Upper*). Densitometric analysis revealed that phosphorylation in the absence of effectors reached a plateau at  $\approx 30$  min, indicative of an equilibrium between phosphorylation and dephosphorylation (Fig. 3*A Bottom*). In a parallel assay, phosphorylation was done in the presence of 100  $\mu$ M toluene. After 50 min of incubation, autophosphorylation activity was  $\approx$  5 times as high as the basal level (Fig. 3*A*).

In a subsequent experiment, TodS was autophosphorylated in the presence of toluene, and, after 50 min, a 500-fold molar excess of unlabeled ATP was added. Samples were taken at different times and analyzed by SDS/PAGE to measure the rate of dephosphorylation. TodS dephosphorylates with a half-life of  $\approx$ 70 min (Fig.

3*B*), which is similar to the half-life of other sensor kinases (14). As mentioned above, TodS contains two sensor domains that probably sense two different signals. In this study, we demonstrate that the addition of a single signal, i.e., toluene, suffices to activate this regulatory system.

**TodS–TodT Transphosphorylation Activity.** The *in vivo* data suggested that TodS–TodT forms a TCS. Attempts were thus made to detect transphosphorylation *in vitro*. Purified TodS and TodT and a mixture of both proteins were incubated in the presence of radioactive ATP for 50 min. As illustrated in Fig. 3*C*, when alone, TodS was autophosphorylated by ATP, which was not the case for TodT when it was alone. However, a band corresponding to TodT appeared in the mixture of both proteins, demonstrating phosphorylation through TodS. This phosphorylation was confirmed by the fact that the band corresponding to TodS had become fainter (Fig. 3*C*).

**IHF Participates in the Activation of P***todx***</del>. Lau** *et al.* **(3) demonstrated** that the TodT-binding box was located far upstream from the RNA polymerase-binding site and was centered at base pair  $-107$  with respect to the transcription start point. This finding implies that activation requires DNA bending to allow productive contacts between the transcriptional regulator and RNA polymerase bound in the downstream element. IHF is involved in DNA bending and in the activation and repression of a number of promoters in which the regulator-binding site is located far from the transcription start point (6, 7). A potential IHF site (AAAAACAATA) was detected between  $-43$  and  $-34$  in  $P_{today}$ , which matched the consensus defined for IHF (6). To study the involvement of IHF in transcription activation, we transferred pMIR66 and pMIR77 into the wild-type KT2440 strain and its isogenic IHF mutant strain and measured the expression from  $P_{today}$  in response to toluene. In both backgrounds, basal expression was similarly low  $(\approx 2$  Miller units). In response to toluene in the culture medium,  $\beta$ -galactosidase levels in KT2440 reached values of  $\approx 4,500$  units; however, induction in the IHF mutant strain was  $1/8$  of that found in the wild type, which supports a direct role for IHF in the activation of  $P_{today}$ .



**Fig. 4.** Identification of TodT and of IHF-binding sites at *PtodX*. DNase I footprints of IHF (*A*) and TodT (*B*). Brackets indicate the protected area. (*C*) Sequence of *PtodX*. The gray shading indicates the region protected by TodT. The dotted outline boxes indicate the two TodT-binding sites. Arrows represent palindromic sequences; the asterisk marks a hyperreactive G; sequences matching the IHF consensus sequence are in bold. The narrow box indicates the fragment protected by IHF. The transcription start site is indicated by an arrowhead, and the  $-10$  base pair position in the promoter is marked with a dot and underlined. (*D*) Sequence alignment of the two TodT binding sites. Conserved nucleotides are boxed.

To verify the role of IHF, we constructed pJLC77 carrying a  $P_{today}^*$  mutant with an altered IHF site fused to 'lacZ, and  $\beta$ -galactosidase activity was measured in *P. putida* DOT-T1E in the exponential phase after induction with toluene. Activity levels with the mutant promoter were 8-fold lower than those obtained with the wild-type promoter (data not shown).

**IHF Binds to**  $P_{today}$  **in Vitro.** To confirm that IHF binds  $P_{today}$  *in vitro*, we carried out EMSA with increasing IHF concentrations and a 352-bp  $32P$ -labeled  $P_{today}$  promoter or the  $P_{today}$ <sup>\*</sup> with an altered IHF site. No binding of IHF to the mutant  $P_{today}^*$  promoter was found (data not shown). In contrast, 100 nM IHF retarded 80% of the



Fig. 5. Specific binding of TodT to  $P_{today}$  EMSA for the binding of TodT to a 352-bp DNA fragment containing the *PtodX* promoter. F, free DNA.

wild-type  $P_{today}$  promoter. From the EMSA, we estimated that the apparent affinity of IHF for its target was  $\approx 70$  nM (data not shown). DNase I footprint assays revealed that IHF protected the  $-24$  to  $-75$  base pair region of  $P_{today}$  (Fig. 4A and *C*), which includes the region identified *in silico*.

**Redefining the TodT-Binding Region in <sup>P</sup>todX.** We used EMSA to study the binding of TodT to  $P_{today}$  (Fig. 5). We observed four bands corresponding to TodT–DNA complexes, which might be indicative of the existence of multiple TodT-binding sites. To identify the TodT-binding site(s), DNase I footprint assays were carried out with 1  $\mu$ M TodT. As shown in Fig. 4 *B* and *C*, the region between base pairs  $-114$  and  $-70$  was protected by TodT. This fragment contained the TodT box centered at base pair  $-107$ , as described in ref. 3. However, there was clear evidence that protection went beyond this site. Inspection of the sequence downstream from the TodT box revealed a second palindromic fragment, termed ''TodT box-2'' (Fig. 4*C*). Sequence alignment of the two TodT boxes revealed a high degree of identity (Fig. 4*D*), and we hypothesize that TodT box-2 represents a second binding site for TodT. The consensus sequence between the two TodT boxes (AAACNNT-NGTTT) can be considered a specific TodT-binding motif.

Activation from the  $P_{today}$  Promoter Requires Contacts with the  $\alpha$ -**Subunit of RNA Polymerase.** A number of positive transcriptional regulators interact with the  $\alpha$ -subunit of RNA polymerase (15, 16). To test whether this interaction occurs in the case for TodT, experiments were carried out in *Escherichia coli* with defects in the  $\alpha$ -subunits bearing pMIR66 and pMIR77. This approach was based on an experimental set-up in which most of the RNA polymerase pool contained a mutant subunit (15–17). The assays were designed to primarily detect a negative effect on transcription. We first tested activation in a mutant background in which  $\alpha$ -C-terminal domain (CTD) lacked 235 residues and found that activity from *PtodX* was  $\approx$  50% of that in the wild type. This observation is consistent with data obtained for other promoters, such as *mtr* regulated by TyrR (18), the TOL plasmid  $P_m$  promoter (17), and the *rha* promoter of *E. coli* (15). Subsequently, we used a series of point mutants exhibiting alanine substitutions (19, 20). TodT-dependent transcription from P<sub>todX</sub> was significantly affected in a background in which  $\alpha$ -CTDL289A or  $\alpha$ -CTDK291A mutants were overproduced, because activity decreased by  $\approx 40\%$  with respect to the wild type. Overproduction of  $\alpha$ -CTD carrying other mutations did not affect the level of expression from  $P_{today}$ . Therefore, the drop in activity in the two  $\alpha$ -CTD mutants seems to result from decreased interactions of  $\alpha$ -CTD with TodT. This finding is in agreement with previous studies showing that the patch of residues around position 289 are involved in interactions between the  $\alpha$ -CTD and the MetR regulator of *E. coli* and the bacteriophage P2 Ogr protein (21).

**In Vitro Transcription Assays.** The results obtained *in vitro* and *in vivo* indicated that expression from  $P_{today}$  requires that TodT be activated by TodS through transphosphorylation in response to toluene. Expression from  $P_{today}$  also involves DNA bending in a process assisted by IHF. To provide unequivocal evidence, we performed



Fig. 6. *In vitro* transcription from  $P_{\text{today}}$ . Transcription assays were performed as described in *Materials and Methods*. The assay performed in the presence of 1.5  $\mu$ M TodS and TodT, 50 nM IHF, and 150  $\mu$ M toluene is shown in lane 1. In lane 4, TodTD57A replaced TodT. IHF and toluene were omitted in lanes 2 and 3, respectively.

*in vitro* transcription assays with linear  $P_{today}$  DNA. Fig. 6 shows that efficient transcription from  $P_{\text{today}}$  took place in the presence of RNA polymerase, TodS, TodT, IHF, and toluene (Fig. 6, lane 1). However, when TodS, TodT, or toluene was omitted, hardly any or no transcription from *PtodX* occurred (for absence of toluene, see Fig. 6, lane 3). In the absence of IHF, expression from *PtodX* was  $\approx$  20–30% of that observed in the complete system (Fig. 6, lane 2). To further confirm that the phosphorylated TodT protein is the activating form of the response regulator, we replaced, in the *in vitro* transcription assay, the TodT protein by a mutant variant that retained the ability to bind target DNA but in which the phosphoaccepting Asp-57 was replaced by alanine. When this mutant regulator was used in *in vitro* transcription assays, no transcript was seen (Fig. 6, lane 4).

### **Discussion**

Soil bacteria sense and respond to environmental cues through a number of TCSs (9). Analyses of annotated bacterial genomes revealed that soil bacteria possess  $\approx$  50 TCSs per genome, which is far greater than the average for other bacteria (22). The soil bacterium *P. putida* KT2440 was shown to have 93 TCSs (8). The large number of structurally similar proteins in a single organism raises the question of specificity of each of these regulatory systems. Here we report assays with *todS* and *todT* mutants that demonstrate that there is no functional interaction between either of the two proteins with other histidine kinases or with transcriptional regulators. We have concluded that the interaction of TodS with TodT is highly specific.

The TOD catabolic enzymes metabolize benzene, toluene, and ethylbenzene. These substrates were found to induce  $P_{today}$  (Fig. 1); however, they induce it to a different degree. Toluene was the most efficient effector of all of the molecules tested, benzene was found to be a good inducer, and the inducing effect of ethylbenzene was modest. Our results showed that there was a high degree of tolerance to different substituents on the aromatic ring and that substitutions in the 3 and 4 positions were better tolerated than substitutions at position 2. This finding suggests that TodS is a protein with broad effector-recognition properties, which is unusual for sensor histidine kinases.

The affinity of TodS for toluene ( $\approx 0.7 \mu$ M) is significantly higher than the binding of effector molecules to other histidine kinase sensors. For instance, CitA has a  $K_d$  of 5.5  $\mu$ M for the binding of citrate (23), and NarX and PhoQ have apparent affinities of  $\approx 35$  $\mu$ M for nitrate and  $\approx 300 \mu$ M for Mg<sup>2+</sup> ions, respectively (24, 25). The high affinity of TodS for toluene assures that bacteria activate transcription and use it as a carbon source at very low concentrations, as expected for a volatile chemical.

TodS contains two signal-sensing domains. Isothermal titration calorimetry showed that toluene bound to NTodS with an affinity of 2.3  $\pm$  0.1  $\mu$ M, whereas no binding was observed with CTodS. This observation provided direct proof that toluene binds to the N-terminal sensor domain. At first sight, our data may appear inconsistent with the findings by Choi *et al.* (4), who showed that TodS mutants within the C-terminal half had a wider effector specificity range. Although we demonstrated that toluene binds to the N-terminal supradomain, an indirect role of the C-terminal region in toluene sensing is likely. This proposal is deduced from the larger enthalpy changes observed for toluene binding to NTodS  $(\Delta H = -18.3 \pm 0.2 \text{ kcal/mol})$  than for the wild-type TodS ( $\Delta H =$  $-5.5 \pm 0.1 \text{ kcal/mol}.$ 

On the basis of sequence similarity to the heme-binding, oxygensensing domain of FixL, it was suggested that the C terminus of TodS was also a heme-containing sensor domain (3). Hemebinding proteins, recombinantly produced in *E. coli*, copurify with heme and show characteristic absorption peaks between 400 and 600 nm (26). Spectral analysis of purified and active TodS showed no maximum peaks in this wavelength range, indicating that it is unlikely that TodS exhibits a heme group.

The TodS protein has a low but measurable basal level of autophosphorylation. We showed that the addition of toluene increases autophosphorylation and results in TodS phosphotransfer to TodT. Phosphorylated TodT functions as the positive regulator. This phenomenon has been corroborated in *in vitro* transcription assays, because, in the absence of TodT or in the presence of mutant TodTD57A, no transcription took place (Fig. 6).

EMSA studies revealed the presence of four retarded bands, indicating that multiple TodT monomers interact with their target DNA. The footprint analyses revealed the existence of two binding sites of similar size and sequence (Fig. 4). The four bands observed in EMSA may be the result of the binding of one TodT monomer per half site in each of the two TodT boxes identified here. Our EMSA and footprint results differ from those originally reported by Lau *et al.*(3), which showed only two retarded bands corresponding to only one TodT binding site. This discrepancy could be due to the fact that, in the initial study, a recombinant TodT-GST fusion protein was used (3). Because GST is similar in size to TodT, this fusion protein may have caused steric hindrance, preventing other TodT molecules from binding to the proximal Tod box-2.

Expression from  $P_{today}$  in an IHF-deficient background was very low and probably reflected the limitations imposed by the absence of the bending protein. Indeed, IHF binds to  $P_{today}$  and protects the region between base pairs  $-24$  and  $-75$ , which is consistent with IHF-mediated DNA bending, allowing a direct interaction between TodT bound to the  $-85$  to  $-107$  boxes and RNA polymerase bound to the downstream promoter site (6). On the basis of the observation that expression from  $P_{today}$  decreased in mutant backgrounds that express RpoA variants, the structure of  $\alpha$ -CTD was resolved and shown to be compactly folded and to contain four  $\alpha$ -helices (27). TodT seems to interact with residues in  $\alpha$ -helix 3 (residues 286–292), a subset of residues also identified in interactions with other positive regulators (21).

Our results support the following model for the mechanism of transcription activation from  $P_{today}$  by the TodS–TodT TCS. TodS exhibits basal autophosphorylation activity, which increases in the presence of toluene. Increased autophosphorylation increases the rate of transphosphorylation of TodT, which is persistently bound to its target sequences in the  $P_{today}$  promoter. Phosphorylation of TodT probably induces conformational changes, which allow or alter the interaction with RNA polymerase in a process assisted by IHF. Once the RNA polymerase–IHF–TodT–*P* scaffold is formed, the *tod* operon is read.

## **Materials and Methods**

**Bacterial Strains, Culture Media, and Plasmids.** The bacterial strains and plasmids used are shown in Table 1 (28–33). *E. coli*strains were grown at 30 $^{\circ}$ C in LB or 2 $\times$  YT medium (for recombinant protein expression) with shaking. *P. putida* was grown on M9 minimal medium with glucose.

**-Galactosidase Assays.** To quantify the expression from the TOD pathway promoter, we used pMIR77  $[P_{today}::lacZ(30)]$  and a mutant *PtodX*\* promoter carrying an altered IHF site (AAAGAGGATA,

mutations are underlined) in pJLC77 ( $P_{today}$ \*:*:lacZ*). Bacterial strains were grown on M9 minimal medium with the appropriate antibiotics without or with the inducer.  $\beta$ -galactosidase activity was determined in permeabilized cells (34).

**Construction of todS and todT Mutants in pMIR66.** The *todS* and *todT* genes in plasmid pMIR66 were disrupted by using the *aphA3* kanamycin (Km)-resistance cassette, which produced no polar effects (32). The resulting plasmids were called pJLC1 (*todS*:*Km*) and pJLC2 (*todT*:*Km*).

**Overexpression and Purification of TodT, TodS, CTodS, NTodS, and IHF.** *todS*, *todT*, and the *todS* mutant variants were cloned independently in  $pET28b<sup>+</sup>$  to yield plasmids  $pTodS$ ,  $pJLTodT$ ,  $pCTodS$ , and pNTodS, which allow the overexpression of these proteins with a His-6 tag. These proteins were purified by using HisTrap columns (Amersham Biosciences). IHF was purified after overexpression of the *ihfA* and *ihfB* genes, as described by Ilves *et al.* (33).

**EMSA.** A 352-bp DNA fragment containing the  $P_{today}$  promoter was amplified by PCR from pMIR77 and end-labeled with  $32P$  as described. Approximately 2 nM labeled DNA ( $\approx$ 1.5  $\times$  10<sup>4</sup> cpm) was incubated with the indicated amounts of purified TodT or IHF for 30 min at 30 $^{\circ}$ C in 10  $\mu$  of binding buffer [50 mM Tris HCl, pH  $8.0/100$  mM KCl/1 mM DTT/10 mM MgCl<sub>2</sub>/10% (vol/vol) glycerol] containing 20  $\mu$ g/ml poly(dI-dC) and 200  $\mu$ g/ml BSA. Electrophoresis in PAGE was done as described in ref. 35.

**DNase I Footprint.** The DNA fragment and buffer used for EMSA was also used for footprinting assays. Approximately 10 nM ( $\approx 10^5$ ) cpm) labeled probe was incubated in the presence and absence of IHF (0.6  $\mu$ M) or TodT (1  $\mu$ M). Reactions were incubated for 30 min before treatment with DNase I ( $10^{-5}$  units/ $\mu$ l). Then DNA was precipitated, suspended in 10 mM Tris/0.1 mM EDTA (pH 8), heated at 90 $\degree$ C for 3 min, and analyzed by using 6.5% (wt/vol) PAGE.

**In Vitro Transcription Assays.** Reactions (20  $\mu$ I) were performed in  $25 \text{ mM Tris-HCl}/9 \text{ mM MgCl}_2/100 \text{ mM KCl (pH 7.5)}$  containing 50 nM  $\sigma^{70}$ -holoenzyme, 20 units of RNasin (Promega), and 5 nM linear  $P_{\text{today}}$  DNA template (680 bp). The mixtures were incubated

- 1. Zylstra, G. J. & Gibson, D. T. (1989) *J. Biol. Chem.* **264,** 14940–14941.
- 2. Mosqueda, G., Ramos-Gonza´lez, M. I. & Ramos, J. L. (1999) *Gene* **232,** 69–76.
- 3. Lau, P. C. K., Wang, Y., Patel, A., Labbe´, D., Bergeron, H., Brousseau, R., Konishi, Y. & Rawlings, M. (1997) *Proc. Natl. Acad. Sci. USA* **94,** 1453–1458.
- 4. Choi, E. N., Cho, M. C., Kim, Y., Kim, C.-K. & Lee, K. (2003) *Microbiology* **149,** 795–805.
- 5. Domínguez-Cuevas & Marqués, S. (2004) *Pseudomonas* (Kluwer, Dordrecht, The Netherlands), Vol. 2, pp. 319–345.
- 6. Pe´rez-Martı´n, J. & de Lorenzo, V. (1997) *Annu. Rev. Microbiol.* **51,** 593–628.
- 
- 7. Berger, D., Naberhaus, F. & Kustu, S. (1994) Proc. Natl. Acad. Sci. USA 91, 103–107.<br>8. Nelson, K. E., Weinel, C., Paulsen, I. T., Dodson, R. J., Hilbert, H., dos Santos,<br>V. A. P., Fouts, D. E., Gill, S. R., Pop, M., Ho **4,** 799–808.
- 9. Ventre, I., Filloux, A. & Lazdunski, A. (2004) *Pseudomonas*, (Kluwer, Dordrecht, The Netherlands), Vol. 2, pp. 257–289.
- 10. Ramos, J. L., Micha´n, C., Rojo, F., Dwyer, D. & Timmis, K. N. (1990) *J. Mol. Biol.* **211,** 373–382.
- 11. Shingler, V. & Pavel, H. (1995) *Mol. Microbiol.* **17,** 505–513.
- 12. Delgado, A., Salto, R., Marque´s, S. & Ramos, J. L. (1995) *J. Biol. Chem.* **270,** 5144–5150.
- 13. Tropel, D. & van der Meer, J. R. (2004) *Microbiol. Mol. Biol. Rev.* **68,** 474–500. 14. Potter, C. A., Ward, A., Laguri, C., Williamson, M. P., Henderson, P. & Phillips-
- Jones, M. K. (2002) *J. Mol. Biol.* **320,** 201–213.
- 15. Holcroft, C. C. & Egan, S. M. (2000) *J. Bacteriol.* **182,** 3529–3535.
- 16. Busby, S. & Ebright, R. H. (1997) *Mol. Microbiol.* **23,** 853–859.
- 17. Ruı´z, R., Marque´s, S. & Ramos, J. L. (2003) *J. Bacteriol.* **185,** 3036–3041.
- 18. Yang, J., Murakami, K., Camakaris, H., Fujita, N., Ishihama, A. & Pittard, A. J. (1997) *J. Bacteriol.* **179,** 6187–6191.
- 19. Tang, H., Severinov, K., Goldfarb, A., Fenyo, D., Chait, B. & Ebright, R. H. (1994) *Genes Dev.* **8,** 3058–3067.

for 10 min at 30°C before the addition of 0.1 mM ATP, CTP, and GTP, 0.05 mM UTP, and 3.6  $\mu$ Ci of [ $\alpha$ -<sup>32</sup>P]UTP (10  $\mu$ Ci/ $\mu$ l) (1  $Ci = 37 GBq$ . After a 20-min incubation, the reactions were chilled at  $4^{\circ}$ C, and  $4 \mu$  of formamide sequencing dye was added. Samples were separated in a 6.5% (wt/vol) PAGE.

**Isothermal Titration Calorimetry.** Measurements were done on a VP microcalorimeter (Microcal, Amherst, MA) at 25°C. TodS was dialyzed against 50 mM Tris·HCl/250 mM KCl/2 mM  $MgCl<sub>2</sub>/2$ mM DTT/0.1 mM EDTA, pH 7.5. One millimole toluene and ethylbenzene solutions were made up in dialysis buffer. The titrations involved  $1.6-\mu l$  injections of toluene or ethylbenzene into a solution of 12–15  $\mu$ M TodS. Titration curves were fitted by a nonlinear least-squares method (ORIGIN software; Microcal) to a function for the binding of a ligand to a macromolecule (36).

**In Vitro Phosphorylation Assays. Autophosphorylation of TodS.** Assays were done in 50 mM Tris·HCl, pH 7.5/200 mM KCl/2 mM MgCl<sub>2</sub>/0.1 mM EDTA/10% (vol/vol) glycerol/10 mM DTT. The autophosphorylation assay was performed at 24°C with 85 pmol purified TodS in a final reaction volume of 100  $\mu$ l in the presence and absence of toluene (100  $\mu$ M). Reactions were initiated by adding radiolabeled ATP (5 nmol ATP containing 1  $\mu$ Ci  $[\gamma^{32}P]ATP$ , and 7.5- $\mu$ l samples were removed at different times. The reaction was stopped by adding  $2 \times$  SDS sample buffer and transferring onto ice. All samples were run on  $SDS/7.5\%$  (wt/vol) PAGE.

**Dephosphorylation of TodS.** Protein was autophosphorylated in the presence of 100  $\mu$ M toluene, as detailed above, for 50 min. A 500-fold molar excess of ATP was added, and samples were removed at different times before analysis by SDS/PAGE.

**Transphosphorylation of TodS–TodT.** A mixture of TodS  $(11 \mu M)$  and TodT (55  $\mu$ M) was incubated in a final volume of 20  $\mu$ l, as described above, for autophosphorylation of TodS. In parallel, TodS and TodT were individually submitted to the same treatment. After 50 min, samples were analyzed by SDS/10% (wt/vol) PAGE.

We thank K. Shashok for improving our use of English and C. Lorente for secretarial assistance. This work was supported by Ministry of Science and Education Grants BIO2003-00515 and GEN2001-4698-CO5-03 and Ministry of the Environment Grant VEM2004-08560.

- 20. Zhou, Y., Merkel, T. J. & Ebright, R. H. (1994) *J. Mol. Biol.* **243,** 603–610.
- 21. Savery, N. J., Rhodus, V. A., Wing, H. J. & Busby, S. J. W. (1995) *Biochem. J.* **309,** 77–83.
- 22. Ashby, M. K. (2004) *FEMS Microbiol. Lett.* **231,** 277–281.
- 23. Gerharz, T., Reinelt, S., Kaspar, S., Scapozza, L. & Bott, M. (2003) *Biochemistry* **42,** 5917–5924.
- 24. Lee, A. I., Delgado, A. & Gunsalus, R. P. (1999) *J. Bacteriol.* **181,** 5309–5316.
- 25. Lesley, J. A. & Waldburger, C. D. (2001) *J. Biol. Chem.* **276,** 30827–30833.
- 26. Nakamura, H., Kumita, H., Imai, K., Iizuka, T. & Shiro, Y. (2004) *Proc. Natl. Acad. Sci. USA*. **101,** 2742–2746.
- 27. Jeon, Y. H., Negishi, T., Yamazaki, T., Fujita, N., Ishihama, A. S. & Kyoguku, Y. (1995) *Science* **270,** 1495–1497.
- 28. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. (1991) *Current Protocols in Molecular Biology* (Wiley, New York).
- 29. Ramos, J. L., Duque, E., Huertas, M. J. & Haı¨dour, A. (1995) *J. Bacteriol.* **177,** 3911–3916.
- 30. Ramos-Gonza´lez, M. I., Olson, M., Gatenby, A. A., Mosqueda, G., Manzanera. M., Campos, M. J., Vı´lchez, S. & Ramos, J. L. (2002) *J. Bacteriol.* **184,** 7062–7067.
- 31. Marqués, S., Gallegos, M. T., Manzanera, M., Holtel, A., Timmis, K. N. & Ramos, J. L. (1998) *J. Bacteriol.* **180,** 2889–2894.
- 32. Me´nard, R., Sansonetti, P. J. & Parsot, C. (1993) *J. Bacteriol.* **175,** 5899–5906.
- 33. Ilves, H., Horak, R., Teras, R. & Kivisaar, M. (2004) *Mol. Microbiol.* **51,** 1773–1785.
- 34. Platt, T., Meueler-Hill, B. & Miller, J. (1972) in *Experiments in Molecular Genetics*, ed. Miller, J. (Cold Spring Harbor Lab. Press, Woodbury, New York) pp. 352–355.
- 35. Guazzaroni, M. E., Tera´n, W., Zhang, X., Gallegos, M. T. & Ramos, J. L. (2004) *J. Bacteriol.* **186,** 2921–2927.
- 36. Wiseman, T., Williston, S., Brandts, J. F. & Lin, L. N. (1989) *Anal. Biochem.* **179,** 131–137.